Liquidia Co. (NASDAQ:LQDA) CEO Sells $263,200.54 in Stock

Liquidia Co. (NASDAQ:LQDA) CEO Roger Jeffs sold 22,343 shares of the business’s stock in a transaction dated Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total value of $263,200.54. Following the sale, the chief executive officer now owns 1,019,177 shares of the company’s stock, valued at approximately $12,005,905.06. This represents a 2.15 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Liquidia Stock Performance

Shares of LQDA stock opened at $12.51 on Friday. The stock has a fifty day simple moving average of $11.26 and a two-hundred day simple moving average of $11.03. The firm has a market capitalization of $1.06 billion, a PE ratio of -7.67 and a beta of 0.23. Liquidia Co. has a 52-week low of $8.26 and a 52-week high of $16.99.

Institutional Trading of Liquidia

Institutional investors have recently made changes to their positions in the business. Whitcomb & Hess Inc. lifted its holdings in Liquidia by 10.2% in the 3rd quarter. Whitcomb & Hess Inc. now owns 11,599 shares of the company’s stock worth $116,000 after purchasing an additional 1,074 shares in the last quarter. Arizona State Retirement System lifted its holdings in shares of Liquidia by 10.7% in the second quarter. Arizona State Retirement System now owns 13,842 shares of the company’s stock worth $166,000 after buying an additional 1,341 shares in the last quarter. Quest Partners LLC bought a new position in shares of Liquidia during the second quarter worth $27,000. Profund Advisors LLC increased its holdings in Liquidia by 31.6% in the 2nd quarter. Profund Advisors LLC now owns 14,434 shares of the company’s stock valued at $173,000 after acquiring an additional 3,466 shares during the last quarter. Finally, DMC Group LLC lifted its stake in Liquidia by 36.7% in the 3rd quarter. DMC Group LLC now owns 13,883 shares of the company’s stock worth $139,000 after purchasing an additional 3,725 shares in the last quarter. Hedge funds and other institutional investors own 64.54% of the company’s stock.

Wall Street Analysts Forecast Growth

LQDA has been the subject of several recent research reports. HC Wainwright restated a “buy” rating and set a $29.00 target price on shares of Liquidia in a research report on Thursday, November 14th. Wells Fargo & Company initiated coverage on shares of Liquidia in a research note on Friday, December 20th. They set an “overweight” rating and a $20.00 price target on the stock. Scotiabank initiated coverage on Liquidia in a research note on Wednesday, October 16th. They issued a “sector outperform” rating and a $30.00 price objective for the company. Lifesci Capital started coverage on Liquidia in a research report on Thursday, October 3rd. They set an “outperform” rating and a $30.00 target price on the stock. Finally, Needham & Company LLC restated a “buy” rating and issued a $19.00 price target on shares of Liquidia in a research report on Thursday, January 9th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Buy” and a consensus target price of $25.38.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).